Available Clinical Trials
Displaying All Clinical Trials (89)
A011106
ALTernate approaches for clinical stage II or III Estrogen Receptor …
ALTernate approaches for clinical stage II or III Estrogen Receptor …
A011202
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection …
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection …
A011401
Randomized Phase III Trial Evaluating the Role of Weight Loss …
Randomized Phase III Trial Evaluating the Role of Weight Loss …
A011502
Alliance A11502 - Aspirin in Preventing Recurrence of Cancer in Patients …
Alliance A11502 - Aspirin in Preventing Recurrence of Cancer in Patients …
A061402
A061402 - Solitary Plasmacytoma of Bone: Randomized Phase III Trial …
A061402 - Solitary Plasmacytoma of Bone: Randomized Phase III Trial …
A071102
A Phase II/III Randomized Trial of Veliparib or Placebo in …
A Phase II/III Randomized Trial of Veliparib or Placebo in …
A081105
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo …
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo …
A091401
A091401 - Randomized Phase II Study of Nivolumab with or …
A091401 - Randomized Phase II Study of Nivolumab with or …
A151216
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). …
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). …
Actinium API-01
A Phase I/II Study of Lintuzumab-Ac225 in Older Patients with …
A Phase I/II Study of Lintuzumab-Ac225 in Older Patients with …
ADVL1622
ADVL1622 - Phase 2 Trial of XL184 (Cabozantinib), an Oral …
ADVL1622 - Phase 2 Trial of XL184 (Cabozantinib), an Oral …
AEWS1221
AEWS1221 - Randomized Phase 3 Trial Evaluating the Addition of …
AEWS1221 - Randomized Phase 3 Trial Evaluating the Addition of …
AGCT1531
AGCT1531: A Phase 3 Study of Active Surveillance for Low …
AGCT1531: A Phase 3 Study of Active Surveillance for Low …
Alexion(AHUS)
An Observational , Non-Interventional, Multi-Center, Multi-National Study of Patients with …
An Observational , Non-Interventional, Multi-Center, Multi-National Study of Patients with …
Alliance A021502
Alliance A021502 - Randomized Trial of Standard Chemotherapy Alone or …
Alliance A021502 - Randomized Trial of Standard Chemotherapy Alone or …
Alliance A031501
A031501 - Phase III randomized “Adjuvant study of MK-3475 (pembrolizumab) …
A031501 - Phase III randomized “Adjuvant study of MK-3475 (pembrolizumab) …
Amgen 20150288
A Phase 2 Open-Label Study Investigating the Safety and Efficacy …
A Phase 2 Open-Label Study Investigating the Safety and Efficacy …
Amgen 20150292
A Phase 2/3 Multi-center Study to Evaluate the Safety and …
A Phase 2/3 Multi-center Study to Evaluate the Safety and …
ARST1321
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A …
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A …
Astex SGI-110-07
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) …
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) …
Bayer 17777
A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus …
A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus …
Biodesix BDX-00146 (INSIGHT)
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and …
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and …
BMS CA209-436
A Phase I/ II Study to Evaluate the Safety and …
A Phase I/ II Study to Evaluate the Safety and …
BMS CA209-592
An Exploratory Study of the Biologic Effects and Biomarkers of …
An Exploratory Study of the Biologic Effects and Biomarkers of …
BMS CA209-812
Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab Vedotin …
Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab Vedotin …
BMS CA209-914
A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination …
A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination …
CALGB 30610
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with …
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with …
CALGB 50801
Response-Based Therapy Assessed By PET Scan in Treating Patients With …
Response-Based Therapy Assessed By PET Scan in Treating Patients With …
Cancer Insight – Melanoma Vaccine
A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an …
A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an …
CanStem111P
A Phase III study of BBI-608 Plus Nab-Paclitaxel with Gemcitabine …
A Phase III study of BBI-608 Plus Nab-Paclitaxel with Gemcitabine …
CC-5013-DLC-002 (ROBUST)
Efficacy and safety study to compare Lenalidomide (CC-55013) plus R-CHOP Chemotherapy …
Efficacy and safety study to compare Lenalidomide (CC-55013) plus R-CHOP Chemotherapy …
CerRx FEN-T14
Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) retinamide, 4-HPR) Emulsion …
Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) retinamide, 4-HPR) Emulsion …
E1910
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed …
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed …
E1A11
A Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone …
A Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone …
E2112
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo …
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo …
E4512
A Phase III Double-Blind Trial for Surgically Resected Early Stage …
A Phase III Double-Blind Trial for Surgically Resected Early Stage …
EA1131
Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. …
Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. …
EA5142
EA5142 - A Randomized Phase III Study of Nivolumab After …
EA5142 - A Randomized Phase III Study of Nivolumab After …
EA6134
EA6134 - A Randomized Phase III Trial of Dabrafenib + …
EA6134 - A Randomized Phase III Trial of Dabrafenib + …
EA8143
EA8143 – A Phase 3 RandOmized Study Comparing PERioperative Nivolumab …
EA8143 – A Phase 3 RandOmized Study Comparing PERioperative Nivolumab …
EAQ 152
COMET - Communication and Education in Tumor Profiling: A Randomized …
COMET - Communication and Education in Tumor Profiling: A Randomized …
Genentech W030070
A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) …
A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) …
Gilead GS-US-339-1559
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in …
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in …
GOG 0263
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation …
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation …
GRAIL-001
The Circulating Cell-Free Genome Atlas (CCGA) Study. GRAIL is using …
The Circulating Cell-Free Genome Atlas (CCGA) Study. GRAIL is using …
IMGN 529-0302
A Phase 2 Study to Evaluate the Efficacy and Tolerability …
A Phase 2 Study to Evaluate the Efficacy and Tolerability …
Janssen 6393593MYF2001
A randomized, single-blind, Multicenter Phase 2 Study to evaluate the …
A randomized, single-blind, Multicenter Phase 2 Study to evaluate the …
Just In Time – 265-101
Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics …
Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics …
Just In Time – DS6051-A-U101
A Phase I, Two-Part, Multi-Center, Non-Randomized, Open Label, Multiple Dose …
A Phase I, Two-Part, Multi-Center, Non-Randomized, Open Label, Multiple Dose …
Just In Time – MS200095-0022
A Phase II single-arm trial to investigate tepotinib in stage …
A Phase II single-arm trial to investigate tepotinib in stage …
Just In Time Pharmatech 265-109
Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally …
Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally …
Just In Time Pharmatech B3281006
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586 VERSUS RITUXIMAB …
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586 VERSUS RITUXIMAB …
Just In Time Pharmatech I4T-MC-JVCY
A Multicenter, Randomized, Double-Blind Study of Erlotinibin Combination with Ramucirumab …
A Multicenter, Randomized, Double-Blind Study of Erlotinibin Combination with Ramucirumab …
Just In Time Pharmatech RX-00201-P2-A-09
A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety …
A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety …
Just In Time Pharmatech RXDX-101-02
Entrectinib For Locally Advanced or Metastatic Solid Tumors That Harbor …
Entrectinib For Locally Advanced or Metastatic Solid Tumors That Harbor …
Just In Time Pharmatech RXDX-105-01
AN OPEN-LABEL, PHASE 1/1B, SINGLE-AGENT STUDY OF RXDX-105 IN PATIENTS …
AN OPEN-LABEL, PHASE 1/1B, SINGLE-AGENT STUDY OF RXDX-105 IN PATIENTS …
Merck MK-3475-177
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in …
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in …
Merck MK-3475-355
A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus …
A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus …
Merck MK-3475-604
A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK- …
A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK- …
Methylgene 516-001
A Phase 1/1b Study of MGCD516 in Patients With Advanced …
A Phase 1/1b Study of MGCD516 in Patients With Advanced …
MK-3475-170
A Phase II Study of Pembrolizumab (MK-3475) in Subjects with …
A Phase II Study of Pembrolizumab (MK-3475) in Subjects with …
NHLBI-MDS
The National Myelodysplastic Syndromes (MDS) Study
The National Myelodysplastic Syndromes (MDS) Study
Novartis Signature CINC280A2201
A Phase II, multicenter, four-cohort study of oral cMET inhibitor …
A Phase II, multicenter, four-cohort study of oral cMET inhibitor …
Novartis Signature CPDR001X2201
A phase II, open-label, randomized controlled study of PDR001 in …
A phase II, open-label, randomized controlled study of PDR001 in …
NRG BR003
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin …
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin …
NRG GY004
A Phase III Study Comparing Single-Agent Olaparib or the Combination …
A Phase III Study Comparing Single-Agent Olaparib or the Combination …
NRG GY006
(reactivated 8.31.17) A Randomized Phase II Trial of Radiation Therapy …
(reactivated 8.31.17) A Randomized Phase II Trial of Radiation Therapy …
NRG-CC004
NRG-CC004 - Phase II Double Blind Dose Finding Trial of …
NRG-CC004 - Phase II Double Blind Dose Finding Trial of …
NRG-GU002
NRG-GU002 - Phase II-III Trial Of Adjuvant Radiotherapy and Androgen …
NRG-GU002 - Phase II-III Trial Of Adjuvant Radiotherapy and Androgen …
NRG-GU003
NRG-GU003: A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation …
NRG-GU003: A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation …
NRG-LU002
NRG-LU002 - Maintenance Systemic Therapy versus Consolidative Stereotactic Body Radiation …
NRG-LU002 - Maintenance Systemic Therapy versus Consolidative Stereotactic Body Radiation …
NSABP B-51
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and …
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and …
NSABP B-55
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study …
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study …
Prolong SGHY-001 (Sanguinate)
An Open-Label Phase 1 Safety Study of SANGUINATE infusion in …
An Open-Label Phase 1 Safety Study of SANGUINATE infusion in …
RTOG 0920
A Phase III Study of Postoperative Radiation Therapy (MRT) +/- …
A Phase III Study of Postoperative Radiation Therapy (MRT) +/- …
RTOG 0924
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without …
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without …
SWOG 1207
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of …
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of …
SWOG 1314
A RANDOMIZED PHASE II STUDY OF CO-EXPRESSION EXTRAPOLATION (COXEN) WITH …
A RANDOMIZED PHASE II STUDY OF CO-EXPRESSION EXTRAPOLATION (COXEN) WITH …
SWOG 1320
S1320, “A Randomized Phase II Trial of Intermittent Versus Continuous …
S1320, “A Randomized Phase II Trial of Intermittent Versus Continuous …
SWOG 1400
Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell …
Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell …
SWOG 1400G
S1400G - A Phase II Study of Talazoparib (BMN 673) …
S1400G - A Phase II Study of Talazoparib (BMN 673) …
SWOG 1400I
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus …
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus …
SWOG 1403
S1403, "A Randomized Phase II/III Trial of Afatinib Plus Cetuximab …
S1403, "A Randomized Phase II/III Trial of Afatinib Plus Cetuximab …
SWOG 1416
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without …
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without …
SWOG 1418
SWOG S1418 - A Randomized, Phase III Trial to Evaluate …
SWOG S1418 - A Randomized, Phase III Trial to Evaluate …
SWOG 1500
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase …
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase …
SWOG 1507
A Phase II Trial of Trametinib with Docetaxel in Patients …
A Phase II Trial of Trametinib with Docetaxel in Patients …
SWOG 1513
Randomized Phase II Study of 2nd Line FOLFIRI versus Modified …
Randomized Phase II Study of 2nd Line FOLFIRI versus Modified …
SWOG S1616
S1616 - A Phase II Randomized Study of Nivolumab (NSC-748726) …
S1616 - A Phase II Randomized Study of Nivolumab (NSC-748726) …
Appointments Available
Request an appointment
Schedule Now
Information Hotline
Have a question? Call us at:
(864) 603-6200
